Genmab A/S’s (GMAB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a $37.00 price objective on the stock, down from their previous price objective of $50.00. HC Wainwright also issued estimates for Genmab A/S’s Q2 2025 earnings at $0.41 EPS, Q3 2025 earnings at $0.44 EPS, Q4 2025 earnings at $0.45 EPS, FY2025 earnings at $1.48 EPS and FY2026 earnings at $1.72 EPS.

A number of other equities analysts also recently commented on GMAB. Sanford C. Bernstein downgraded Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a report on Thursday, February 13th. Finally, Truist Financial cut their price target on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.17.

Genmab A/S Stock Performance

Shares of GMAB opened at $18.81 on Wednesday. The stock has a 50 day moving average price of $20.48 and a 200 day moving average price of $21.31. Genmab A/S has a one year low of $17.24 and a one year high of $30.41. The stock has a market capitalization of $12.45 billion, a price-to-earnings ratio of 10.81, a PEG ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Marotta Asset Management raised its holdings in shares of Genmab A/S by 5.8% in the 1st quarter. Marotta Asset Management now owns 13,532 shares of the company’s stock valued at $265,000 after buying an additional 739 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after purchasing an additional 827 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC boosted its stake in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.